Two mutations (K141E, K141N) in the small heat shock protein (sHSP) HSP22 (HSPB8) are associated with the inherited peripheral motor neuron disorders distal hereditary motor neuropathy type II and axonal Charcot-Marie-Tooth disease type 2L. HSP22 is known to form homodimers, heterodimers with other sHSPs, and larger oligomers. In an effort to elucidate the cellular basis for these diseases, we have determined the ability of mutant HSP22 to interact with itself, with wild-type HSP22, and with other sHSPs that are abundant in neurons. Using the yeast two-hybrid method, quantitative fluorescence resonance energy transfer in live cells, and cross-linking, we found aberrantly increased interactions of mutant HSP22 forms with themselves, with wild-type HSP22, and with the other sHSPs, ␣B-crystallin, and HSP27. Interaction with HSP20 was not affected by the mutations. The data suggest that each mutant form of HSP22 has a characteristic pattern of abnormal interaction properties. A mutation (S135F) in HSP27 that is also associated with these disorders showed increased interaction with wild-type HSP22 also, suggesting linkage of these two etiologic factors, HSP22 and HSP27, into one common pathway. Increased interactions involving mutant sHSPs may be the molecular basis for their increased tendency to form cytoplasmic protein aggregates, and for the occurrence of the associated
disorders are clinically and genetically heterogeneous, and the number of identified genes that, when mutated, cause these diseases has risen substantially in recent years (2, 3) . Among the affected genes is the gene encoding the small heat shock protein (sHSP) 22 (HSP22, also known as HSPB8, H11; gene name: HSPB8) (4, 5) . So far, five families with dHMN type II or CMT type 2L carrying mutations in the HSPB8 gene have been identified (6, 7) . The two mutations known to date affect the "hot spot" amino acid residue Lys141 in the wild-type HSP22 ( wt HSP22) protein sequence changing it to either Glu ( K141E HSP22) or Asn ( K141N HSP22). In affected individuals, both the wild-type and mutant HSPB8 alleles are expressed, and both mutants have dominant gain-of-function characteristics (6) .
In mammals, several of the sHSPs such as HSP22, HSP27, ␣B-crystallin (␣B-Cry), and HSP20 are expressed in a variety of organs and tissues, including neuronal tissues (8) . sHSPs form dimers that are the basic building blocks for higher molecular mass oligomeric structures or complexes (9, 10) . In addition to homodimers, sHSPs can form heterodimers and mixed heterooligomers, although not all possible sHSP interactions may occur in cells (11, 12) . Most cells contain sHSP species ranging from dimers to approximately quadragintamers. This mixed complex formation is a prominent, although not well understood, property of sHSPs. HSP22 has been shown to form homodimers and also heterodimers with HSP27, ␣B-Cry, HSP20, and other sHSPs (12, 13) . Recently, a number of mutations in HSP27 ( mu HSP27) and ␣B-Cry has been identified that are also associated with neuropathies and with myopathies. These mutations include R127W HSP27, S135F HSP27, R136W HSP27, T151I HSP27, P182L HSP27, and P182S HSP27 (all associated with dHMN and/or CMT), R120G ␣B-Cry, 464⌬CT ␣B-Cry, and Q151X ␣B-Cry (all associated with desmin-related or myofibrillar myopathy), and R157H ␣B-Cry (associated with dilated cardiomyopathy) (14 -19) .
A hallmark of many neurodegenerative diseases, including Parkinson, Alzheimer, and Alexander diseases, is the misfolding and precipitation of proteins in the nervous system referred to as aggresome or amyloid formation (20) . Each such amyloid disease usually involves the aggregation of a specific protein, with a range of other proteins being also incorporated into the aggregates. sHSPs are found in at least one type of these aggregates together with intermediate filament proteins (21) . As far as studied, the neuropathy-and myopathy-associated mutant forms of HSP22, HSP27, and ␣B-Cry also form aggregates, which is thought to contribute to the manifestation of the associated diseases (6, 14, 22, 23) .
Using the yeast two-hybrid (TH) method, chemical cross-linking (CL), and quantitative fluorescence resonance energy transfer (qFRET) in live mammalian cells, we show herein that both mutant HSP22 ( mu HSP22) proteins are capable of interacting with themselves, with wt HSP22, and with other sHSPs, and that the mu HSP22 proteins have abnormally increased, although different, interaction properties. Similarly, disease-associated S135F HSP27 has an increased interaction with wt HSP22 as compared with wild-type HSP27 ( wt HSP27), thus providing a rationale for the observation that mutations in both, HSP22 ( K141E HSP22, K141N HSP22) and HSP27 ( S135F HSP27) result in similar disease phenotypes.
It is hypothesized that these abnormal sHSP interactions are the molecular basis for both the formation of cytoplasmic protein aggregates and eventually for the development of the associated disorders dHMN type II and CMT type 2.
MATERIALS AND METHODS

Vector constructs
TH vector constructs were made using the vectors pGBKT7, pGADT7, and pACT2 (BD Biosciences, San Jose, CA). Cyan (CFP) and citrine (CIT) fluorescent sHSP fusion protein expression vectors were made using the vectors peCFPN1 (BD Biosciences) and peCITN1 (24) . myc-HSP22 constructs were made using the vectors pcDNA3.1-myc (Invitrogen, Carlsbad, CA). The mutant forms of HSP22 were made by site-directed mutagenesis using the QuickChangeXL kit (Stratagene, La Jolla, CA). More detailed cloning information is given in Table 1 and in previous publications (12, 13, 25) .
Two-hybrid method
Small-scale sequential transformation of the yeast strain AH109 was performed as described in the manufacturer's instructions (BD Biosciences). The yeast was first transformed with constructs pGBKT7-wt HSP22 [13] (the underlined numbers in brackets designate the used vector constructs as specified in Table 1 ), pGBKT7-K141E HSP22 [15] , or pGBKT7-K141N HSP22 [17] , and grown on -Trp medium as described previously (13) . In the second step, the yeast were transformed with the complementary vectors, as specified in Figs. 2A, 5A, and 7A. Selection was on -Trp,-Leu,-His medium for the phenotype Hisϩ (growth). Additionally, the colonies were analyzed for the phenotype LacZϩ (blue color) using the colony filter lift assay. The interaction assays were considered positive only if both reporter genes were activated. For the negative TH controls, yeasts were transformed with each vector alone and tested on -Trp/-Leu/-His medium (not shown). Additionally, yeasts were cotransformed with each vector and with the "empty" partner vector (controls C1-C14 in Figs. 2B, 5B, 7B). In none of these controls were the reporter genes activated.
Live cell imaging and quantitative fluorescence resonance energy transfer (qFRET)
CFP-and CIT-sHSP fusion protein expression vectors were used for these experiments. CIT is a variant of the yellow fluorescent protein (YFP) that is superior for qFRET (24) . COS-7 cells were grown in glass-bottom six-well culture plates (MatTek Corporation, Ashland, MA) in Dulbecco's modified Eagle medium (DMEM) (Life Technologies, Inc., Carlsbad, CA) supplemented with 10% fetal calf serum (Invitrogen) in a 5% CO 2 humidified atmosphere at 37°C. Cells were transfected at ϳ60% confluency with 0.75 g (single construct) or 1.5 g (two constructs) vector DNA using FuGene6 (Roche Applied Science, Indianapolis, IN). Twenty-four h later, the live cells that express the CFP-and CIT-sHSP fusion proteins were washed 2 times with PBS and kept in DMEM medium without phenol red (Invitrogen) for collecting the fluorescence images at 37°C.
For fluorescence imaging, an inverted epifluorescence microscope (Eclipse TE-2000 U; Nikon, Melville, NY) equipped with a 100 W Mercury Arc-lamp, exciter filters 430/25 and 500/20, a dichroic microscope filter 86002bs, and with a 505dcxr Dual View Micro Imager MSMI.DV.CC (Optical Insights, Tucson, AZ) with the emission filters 470/30 and 535/30, was used. Images were collected by a digital CoolSnap CCD camera (Photometrics, Huntington Beach, CA) and using Metamorph image processing software version 6.2r5 (Molecular Devices, Sunnyvale, CA).
HSP22-CIT fusion proteins (both wild-type and mutants) expressed in COS-7 cells formed aggregates. The proportion of cells with aggregates was determined 24 h after transfection. For counting, randomly selected microscopic fields were evaluated using a Plan fluor ELWD 40x/0.6 objective lens (Nikon).
We applied the qFRET method to quantify apparent fluorescence resonance energy transfer efficiencies as indicators of protein interactions (24, 26) . The configuration of the microscope was as described above, with the exception that a Fluor ELWD 40x/1.3 oil Dic H objective lens (Nikon) was used. I A , I D , and I F images from at least 30 microscopic fields per sample group were acquired and background/shadingcorrected prior to computation by the qFRET algorithm. The apparent FRET efficiencies E A and E D were determined (E A , apparent acceptor efficiency calculated from sensitized emission and dependent on the fraction of acceptor in complex; E D , apparent donor efficiency calculated relative to donor fluorescence and dependent on the fraction of the donor in complex). E A and E D are proportional to the fraction of the interaction partners in complex. The calculated output data were expressed as the apparent average fluorescence resonance energy transfer efficiency, or AAFE ([E A ϩ E D ]/2). Only cells without protein aggregates were included in this analysis. As negative control, the cells were transfected with the "empty" CFP (peCFPN1) and CIT (peCITN1) vectors. Expression of the corresponding fluorescent proteins resulted in a minor interaction signal that defined the baseline level. AAFE values that were significantly different from that signal indicated interaction.
Toxicity assay
COS-7 cells were transfected with wt HSP22-CIT [4] , K141E HSP22-CIT [6] , and K141N HSP22-CIT [8] , or transfected with the "empty" CIT vector for control. Toxicity of the various HSP22-CFP species was evaluated after 24 h by determining the percentage of dead cells in each sample group using the Live/Dead Viability/Cytotoxicity kit (Invitrogen).
Cross-linking
HEK-293T cells were grown at 37°C in poly-l-lysine-pretreated 6-well plates in DMEM medium supplemented with 10% fetal calf serum in a 5% CO 2 humidified atmosphere. Cells were transfected at ϳ80% confluency with 2 g of vector DNA of myc-tagged HSP22 species [1, 2, 3] using Lipofectamine 2000 (Invitrogen). 48 h later, cells were collected and washed three times with ice-cold PBS (pH 8.0). Cells were incubated with either 0.5 or 5 mM of the homobifunctional amine-reactive cross-linker disuccinimidyl suberate (DSS; Pierce, Rockford, IL) for 30 min at room temperature. The reaction was stopped by adding Tris-HCl (pH 7.5) to 15 mM final concentration. Fifteen minutes later, 1 vol of sample buffer (125 mM Tris-HCl, pH 6.8; 4% SDS; 20% glycerol; 400 mM dithiothreitol; 0.01% bromphenol blue) was added. After a brief sonication and boiling for 5 min, the samples were analyzed by SDS-PAGE and Western blot analysis. A monoclonal antimyc primary antibody (Ab) (Sigma, St. Louis, MO) and a goat antimouse horseradish-coupled secondary Ab (Pierce) were used for immunodetection.
Data and statistics
Quantitative data are expressed as mean Ϯ se. Unpaired Student's t test was applied to compare results between sample groups. The number of counted cells for each value was at least 400 in Fig. 1E (4ՅnՅ7), and ϳ300 in the viability assay (11ՅnՅ13). The number of cells analyzed by the qFRET method were at least 47 in Figs. 3B, 6B, 7D (nՆ47). Differences between groups were considered statistically significant if P Ͻ 0.05.
RESULTS
Intracellular localization of mu HSP22 and formation of protein aggregates
After transfection of mammalian cells with aggregateforming proteins, these structures form in the cytoplasm in a time-dependent process usually starting at multiple foci. These multifoci type aggregates are then transported along microtubules to finally form a pericentrosomal mass (27, 28) . Coexpression of aggregate- a For each primer pair, the first and second numbers refer to the forward and reverse primers, respectively. Primers: 1, 5Ј-ctaagaacttcacagagaaaatccagcttcctgc; 2, 5Ј-gcaggaagctggattttctctgtgaagttcttag; 5Ј-gtttctaagaacttcacaaacaaaatccagcttcctgcagagg; 4, 5Ј-cctctgcaggaagctggattttgtttgtgaagttcttagaaac; 5, 5Ј-agaacttcacaaacaaaatccagct; 6, 5'-agctggattttgtttgtgaagttct; 5, 5Ј-ccggaattcagtgtggtggaattcaac; 6, 5Ј-cggggtacccaggtacaggtgacttcc; 7, 5Ј-ccggaattcatggagatccctgtgcctg; 8, 5Ј-cggggtacccacttggctgcggctggcg; 9, 5Ј-aaaaaagaattcgaatgaccgagcgcc; 10, 5Ј-aaaaaactcgagctcacttggcggcag; 11, 5Ј-atggctacatcttccggtgcttcacg; 12, 5Ј-tgaagcaccggaagatgtagccatgc; 13, 5Ј-aaaaaaaagcttatgaccgagcgccgc; 14, 5Ј-aaaaagaattcgcacttggcggcagt.
b Sun et al., 2004 (13) . c Fontaine et al., 2005 (12) . d Sun et al., 2006 (25) . e pACT2 is compatible with pGBKT7 in TH assays forming mutant sHSPs with wild-type sHSPs can attenuate this aggregate formation (29) . To estimate the aggregate-forming potency of the used mu HSP22-CIT fusion proteins, and to relate it to the interaction data (see below), we determined the proportion of aggregate-containing cells when mu HSP22 was expressed alone or together with wt HSP22, HSP20, ␣B-Cry, or wt HSP27 as CFP fusion proteins.
In control experiments CIT and CFP alone did not form aggregates when expressed in COS-7 cells. Representative cells with nearly even cytoplasmic distribution of CIT and CFP are shown in Fig. 1A . Similarly, the expression of any of the used constructs of HSP20-CFP [10] , ␣B-Cry-CFP [11] , and wt HSP27-CFP [12] alone did not result in any significant aggregate formation (not shown). In contrast, 24 h after transfection, wt HSP22-CIT [4] , K141E HSP22-CIT [6] , or K141N HSP22-CIT [8] resulted in the formation of cytoplasmic multifoci type aggregates (Fig. 1B) , although with a different incidence (see below). Coexpression of both forms of mu HSP22-CIT [6, 8] with wt HSP22-CFP [5] resulted in colocalization in the aggregates (Fig. 1C) , while at the same time, the proportion of cells containing aggregates was decreased (see below). Similarly, coexpression of both mu HSP22-CIT forms [6, 8] and of wt HSP22-CIT [4] with HSP20-CFP [10] , ␣B-Cry-CFP [11] , and wt HSP27-CFP [12] resulted in recruitment of these sHSPs into aggregates (Fig. 1D) , as well as again lessening the proportion of cells containing aggregates (see below).
To quantify both the tendency of the mu HSP22 proteins to form aggregates and the ability of wild-type sHSPs to attenuate aggregate formation, the proportion of cells containing aggregates after transfection was calculated in these experiments. Expression of wt HSP22-CIT [4] resulted in aggregate formation in ϳ17% of cells. This defined the baseline level for this construct in COS-7 cells (Fig. 1E, control group) . Expression of K141E HSP22-CIT [6] and K141N HSP22-CIT [8] resulted in a slightly and greatly increased aggregate formation affecting ϳ21% and 54%, respectively, of the transfected cells. Thus, both mu HSP22 proteins have increased propensities to form aggregates, although to a different extent. Coexpression of wt HSP22-CFP [5] with K141E HSP22-CIT [6] or with K141N HSP22-CIT [8] significantly decreased aggregate formation to ϳ15% and 37% (Fig. 1E, HSP22 group) , respectively, as compared to expression of mu HSP22 alone (Fig. 1E , control group).
To determine the effect of other sHSPs (HSP20, ␣B-Cry, wt HSP27) on aggregate formation of wt HSP22 and mu HSP22, similar coexpression experiments were performed. In general, coexpression of HSP20-CFP [10] , ␣B-Cry-CFP [11] , and wt HSP27-CFP [12] attenuated the formation of aggregates that was caused by expression HSP22-CIT [8] (Fig. 1E; HSP20 , ␣B-Cry, and HSP27 groups), as compared to the expression of the corresponding HSP22 species alone ( Fig. 1E ; control group). However, the obtained patterns were different for each of the tested sHSPs. For example, aggregate formation by K141N HSP22-CIT was more effectively attenuated by HSP20 or ␣B-Cry than by wt HSP27, whereas aggregate formation by wt HSP22-CIT was most effectively attenuated by ␣B-Cry or wt HSP27. It has been reported that ectopic expression of both forms of mu HSP22 in N2a neuronal cells reduced cell viability significantly 48 h after transfection (6) . Aggregate formation frequently correlates with reduced cell viability and disease, although mature aggregates may be relatively benign or even protective as compared to early prefibrillar aggregates (20) . In the context of our study, reduced cell viability due to the possible toxicity of the various HSP22 species could interfere with the data presented in Fig. 1E Additionally, these data demonstrate that in all settings, a significant proportion of cells is not affected by aggregate formation 24 h after transfection. In these cells, the sHSPs show a relatively even distribution in the cytoplasm (cf . Figs. 3A, 6A, 7C ). Such cells were selected for qFRET measurements as described below.
Interactions of mu
HSP22 with itself and with wt HSP22
We have determined the ability of both (Fig. 2A) (Fig. 2B) .
For the qFRET analysis, COS-7 cells were transfected with various vector pairs to be analyzed. Twenty-four hours later, cells without aggregates and with even cytoplasmic distribution of the expressed proteins were selected. Representative cell images for all analyzed HSP22 pairs are shown in Fig. 3A . The AAFE values obtained for all tested interactions were significantly different from the negative control, thus indicating interaction (Fig. 3B) [3] . Forty-eight hours later, cells were harvested, washed with PBS, and treated with 0.5 mM or 5 mM DSS, a homobifunctional cross-linker. The crosslinked proteins were then processed for SDS-PAGE, and Western blot analysis was performed using a mycspecific Ab detection system (Fig. 4) . CL of wt HSP22, Previously it was shown that wt HSP22 interacts with HSP20, ␣B-Cry, and wt HSP27 (12, 13) . To determine potentially abnormal interaction properties with these sHSPs, both mu HSP22 forms were probed in TH and qFRET assays.
The TH data suggested that both K141E HSP22 [15] and K141N HSP22 [17] interact with HSP20 [20] , ␣B-Cry [21] , and wt HSP27 [19] , in a manner similar to wt HSP22 [13] (Fig. 5A) . Within the limits of this method, no differences in the interaction stoichiometry between mu HSP22 and wt HSP22 were observed. All negative TH controls (C7-C12) provided negative results, as expected (Fig. 5B) .
The qFRET analysis in doubly transfected cells was performed as described above. In contrast to HSP22-CIT fusion proteins, which are located in both the cytoplasm and the nuclei, the fusion proteins HSP20-CFP, ␣B-Cry-CFP, and wt HSP27-CFP were largely excluded from nuclei. Representative CFP images of cells coexpressing these three sHSP-CFP fusion proteins together with the various forms of HSP22 are shown in Fig. 6A . The AAFE values for K141E HSP22 [6] or K141N HSP22 [8] with HSP20 [10] as interacting partner were not significantly different from that of wt HSP22 [4] , suggesting that the mutations do not affect this interaction (Fig. 6B, HSP20 group) . In contrast, the AAFE values for K141E HSP22 [6] or K141N HSP22 [8] with ␣B-Cry [11] as interacting partner were moderately, although significantly, increased (␣B-Cry group) as compared with wt HSP22 [4] , suggesting that this [8/9] as CIT and CFP fusion proteins as indicated. The bar indicates 50 m. B) AAFE as determined by the qFRET method in doubly transfected COS-7 cells expressing the various HSP22 species, as indicated. The measured interactions, and the constructs used were as in A. All sample values were significantly different from the control. Significant differences from the wt HSP22/ wt HSP22 interaction ‫,)ء(‬ from the wt HSP22/ K141E HSP22 interaction (ϩ), and from the K141E HSP22/ K141E HSP22 interaction (ϫ) are indicated where appropriate. Abbreviations: C, control; other abbreviations are as in Fig. 1 . HSP22 [3] cDNAs, or were not transfected, as indicated. Forty-eight hours later, cell proteins were crosslinked with 0.5 mM or 5 mM DSS, or were left untreated. After CL, cells were harvested and processed for SDS-PAGE/Western blot analysis using a myc-specific Ab. Scale on the left: positions of molecular mass marker proteins. Scale on the right: positions of HSP22 monomers (1), HSP22 dimers (2), possibly HSP22 tetramers (4), and of the endogenous myc protein (myc).
interaction is affected by both mutations. The AAFE values for both mu HSP22 proteins were similar when compared to each other. Finally, the AAFE values for K141E HSP22 [6] and K141N HSP22 [8] were moderately and strongly, respectively, increased with wt HSP27 [12] as interacting partner (HSP27 group), as compared with wt HSP22 [4] . Thus, both mutations result in increased interaction with wt HSP27, although to a different extent.
Taken together, these data suggest that both mu HSP22 proteins interact with HSP20, ␣B-Cry, and wt HSP27. Additionally, the data reveal increased interactions of both mu HSP22 proteins with ␣B-Cry and wt HSP27, while the interaction with HSP20 was not affected.
Because of the possibility that mutations in HSP27 affect the HSP22/HSP27 interaction in a similar way, we examined interaction properties of S135F HSP27, one of the mu HSP27 forms, which is associated with both dHMN type II and CMT type 2F (14) . The TH data show that S135F HSP27 [23] or wt HSP27 [22] interact similarly with wt HSP22 [13] (Fig. 7A) . The negative TH controls (C7, C13, C14) provided, as expected, negative results (Fig. 5B, 7B) . For the qFRET analysis, COS-7 cells were doubly transfected to express S135F HSP27-CIT [25] or wt HSP27-CIT [24] , together with wt HSP22-CFP [5] . Representative cells with almost even cytoplasmic distribution of these fusion proteins are shown in Fig. 7C . The AAFE values obtained for the interactions of S135F HSP27 or wt HSP27 with wt HSP22 were significantly different from the negative control, thus indicating interaction (Fig. 7D) . The AAFE for the S135F HSP27/ wt HSP22 interaction was significantly greater than for the wt HSP27/ wt HSP22 interaction. Thus, this mu HSP27 form affects the HSP22/HSP27 interaction in a way similar to the two mu HSP22 forms.
DISCUSSION
In the inherited disorders dHMN and CMT, the known affected genes are involved in very different cellular functions and pathways, including RNA processing and metabolism (glycyl-tRNA synthetase, senataxin, immunoglobin -binding protein2), cytoskeletal functions (dynactin, KIF1B, neurofilament L protein), and others, thus illustrating the remarkable genetic heterogeneity that underlies these diseases. An additional group of affected genes is formed by the sHSPs (2) (3) (4) (5) . To date, it is not clear how mutations in these seemingly unrelated genes cause similar or even identical disease phenotypes. Figure 5 . TH assays of the interactions of mu HSP22 with other sHSPs. A) Assays to determine the interactions of K141E HSP22 [15] and K141N HSP22 [17] with HSP20 [20] , ␣B-Cry [21] , and wt HSP27 [19] . The interactions with wt HSP22 [13] served as positive controls. B) Negative TH controls: C7, C8, C9, pACT2 with wt HSP22 [13] , K141E HSP22 [15] or K141N HSP22 [17] , respectively; C10, C11, C12, pGBKT7 with HSP20 [20] , ␣B-Cry [21] , or HSP27 [19] , respectively. Reporter gene designation and abbreviations are as in Fig. 2 . K141E HSP22) are indicated. Abbreviations are as in Fig. 3 .
All of the currently eight known mutations in HSP22 and HSP27 are associated with the neuropathies dHMN type II and CMT type 2 (6, 7, 14 -16) . In contrast, the currently four known mutations in ␣B-Cry, other than those which affect exclusively the lens of the eye, are associated with the myopathies desmin-related (myofibrillar) myopathy and dilated cardiomyopathy (17) (18) (19) . Thus, although ␣B-Cry does interact with both HSP22 and HSP27 (11, 12, 30) , mutations in this protein have somewhat different pathological consequences. This may indicate a different functional role for ␣B-Cry, as compared to HSP22 and HSP27, or alternatively, it simply may reflect the high abundance of ␣B-Cry in heart and skeletal muscle tissues (31) . Another remarkable observation is that all these mutations have dominant gain-of-function characteristics. The presence of the wild-type proteins in the diseased tissues does not prevent the manifestation of the diseases. A plausible explanation is that the insertion of only a few mutated protein molecules into heterooligomeric sHSP complexes results in the formation of malstructured and therefore malfunctioning sHSP complexes. Thus, the model, based on aberrant sHSP-sHSP interactions may provide the rationale for the genetic dominance, as is seen in these diseases. In the case of the neuropathies, the diseases show a late onset, indicating that the cell damage, due to malfunctioning sHSP complexes, accumulates over years before it becomes clinically manifest.
The data collected in this study show that both disease-associated forms of mu HSP22 interact with wt HSP22, with themselves, and with the other sHSPs HSP20, ␣B-Cry and wt HSP27. Some of the interactions involving mu HSP22 exhibited increased stoichiometry, while others remained unchanged. None of the interactions was weakened. Each of the two mu HSP22 forms had a characteristic pattern of abnormal interactions. A summary of the abnormal interactions as determined for K141E HSP22 is given in Fig. 8A and that for K141N HSP22 in Fig. 8B . The interaction characteristics of K141N HSP22 deviated more from wt HSP22 than the characteristics of K141E HSP22. Whether this correlates to the clinical phenotype, e.g., the severity of the associated diseases, remains to be determined.
We have investigated the interaction of one of the HSP27 mutants ( S135F HSP27) with HSP22 and found increased interaction with wt HSP22. This suggests that mutations in either HSP22 or HSP27 may result in a similarly abnormal increase in the interaction between both proteins (Fig. 8C ) and that this increased HSP22/HSP27 interaction then contributes to the manifestation of both motor neuron diseases. These data may reflect the existence of a relationship between the three etiologic factors K141E HSP22, K141N HSP22, and S135F HSP27 in one common pathway. Although principally all proteins, depending on the conditions, are prone to aggregate formation, mutant proteins, in general, have a higher tendency to form aggregates (32) . Therefore, it is not surprising that [13] . The interaction of wt HSP27 [22] with wt HSP22 [13] served as positive control. B) Negative TH controls: C7 (cf. Fig 5) Fig. 2 . Abbreviations: F, S135F HSP27; other abbreviations are as in Fig. 3 . Fig. 8 Schematic of identified abnormal interactions at the dimer level involving diseaseassociated K141E HSP22, K141N HSP22, and S135F HSP27. Single interactions were found unchanged ( ), moderately increased ( ), or greatly increased ( ) in comparison with the corresponding wild-type sHSPs in the same interaction. A) K141E HSP22 has moderately increased interactions with itself, ␣B-Cry, and wt HSP27. B) K141N HSP22 has greatly increased interactions with itself, wt HSP22, and wt HSP27, and moderately increased interaction with ␣B-Cry. C) S135F HSP27 has moderately increased interaction with wt HSP22. Note that each mu HSP22 form has a characteristic, abnormal interaction pattern. That mu HSP22 has increased interaction with wt HSP27 and that S135F HSP27 has increased interaction with wt HSP22 and mutations in HSP22 or HSP27 resulting in a similar disease suggest that both mutant proteins may act through the same mechanism.
both mutant forms of HSP22 have an increased tendency to form aggregates (Fig. 1E) , similarly as was reported previously (6) . For three other sHSP mutants, including P182L HSP27 (22) , S135F HSP27 (14) , and R120G ␣B-Cry (17, 23) , this has been also demonstrated. Although the R120G ␣B-Cry aggregates meet the criteria for true ameloid fibrils or aggresomes (23) usually seen in neurodegenerative diseases, this characteristic remains to be verified for the mutant HSP22 and HSP27 aggregates. Although protein aggregates frequently are associated with disease, their significance for cell viability is not clear. Aggregates may be cytotoxic, they may be inert, or they even may be the end product of a cellular "detoxifying" response (33) . What seems clear is that large mass end products of the aggregation process are relatively benign as compared to the more toxic early prefibrillar aggregates. Cytotoxicity for both mutant forms of HSP22 in transfected neuronal cells has been demonstrated previously (6) . The fact that we could not detect any cytotoxic effects of either mutant form of HSP22 in COS-7 cells may have its cause in the cell type used. More likely, however, is that 24 h after transfection, the toxicity of the aggregates, be it in the prefibrillar or in the fibrillar stage, has not yet developed, as it would several days after transfection. The fact that no cytotoxic effects distort the data, as shown in Fig. 1E , strengthens the conclusion that both mutant forms of HSP22 have an increased tendency to form aggregates as compared to wt HSP22. This increased tendency of both mu HSP22 proteins to form aggregates may well be caused by their abnormally increased ability to interact with wt HSP22 and with some of the other sHSPs. In summary, the data presented here provide an initial rationale for the pathogenesis of the mu HSP22-associated motor neuropathies dHMN and CMT. The precise mechanism by which the aberrant interaction and aggregate forming properties of mu HSP22 translate into the slow death of neurons remains to be elucidated. 
